Venous thromboembolism associated with cyproterone acetate in combination with ethinyloestradiol (Dianette®): Observational studies using the UK General Practice Research Database

Pharmacoepidemiology and Drug Safety

Volumn 13, Issue 7, 2004, Pages 427-436

  Seaman, H E ^a   de Vries, C S ^a   Farmer, R D T ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

Acne; Cyproterone acetate; Ethinyloestradiol; General Practice Research Database; Polycystic ovary syndrome; Venous thromboembolism

Indexed keywords

DIANE; ORAL CONTRACEPTIVE AGENT;

ACNE; ADOLESCENT; ADULT; ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; FEMALE; GENERAL PRACTICE; HIRSUTISM; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MEDICAL RESEARCH; OVARY POLYCYSTIC DISEASE; PHARMACOEPIDEMIOLOGY; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; UNITED KINGDOM; VENOUS THROMBOEMBOLISM;

ACNE VULGARIS; ADOLESCENT; ADULT; ANDROGEN ANTAGONISTS; CASE-CONTROL STUDIES; CYPROTERONE ACETATE; DATABASES, FACTUAL; DRUG COMBINATIONS; ESTROGENS; ETHINYL ESTRADIOL; FEMALE; GREAT BRITAIN; HUMANS; INCIDENCE; POLYCYSTIC OVARY SYNDROME; VENOUS THROMBOSIS;

EID: 3242879630     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.896     Document Type: Article

References (22)

1. Taylor AE. Understanding the underlying metabolic abnormalities of polycystic ovary syndrome and their implications. Am J Obstet Gynecol 1998; 179: S94-S100.
2. Solomon CG. The epidemiology of polycystic ovary syndrome: prevalence and associated disease risks. Endocrinol Metab Clin North Am 1999; 28: 247-263.
3. Kelly CJ, Connell JM, Cameron IT, Gould GW, Lyall H. The long term health consequences of polycystic ovary syndrome. BJOG 2000; 107: 1327-1338.
4. Atiomo WU, Fox R, Condon JE, et al. Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clin Endocrinol 2000; 52: 487-492.
5. Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol 2000; 52: 595-600.
6. Medicines Compendium (2002) Summary of product characteristics for Dianette. Electronic Medicines Compendium. www.emc.vhn.net/professional. 2002. Datapharm Publications Ltd.
7. Seaman HE, de Vries CS, Farmer RDT. Differences in the use of combined oral contraceptives amongst women with and without acne. Hum Reprod 2003; 18(3): 515-521.
8. Committee on Safety of Medicines. Combined Oral Contraceptives and Thromboembolism. Committee on Safety of Medicines: London, 1995.
9. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-1582.
10. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-1588.
11. Farmer RDT, Lawrenson RA, Todd J-C, Williams TJ, MacRae K. Oral contraceptives and venous thromboembolic disease: analysis of the UK General Practice Research Database and the UK MediPlus Database. Hum Reprod Update 1999; 5: 688-706.
12. Farmer RDT, Lawrenson RA, Todd J-C, et al. A comparison of the risks of venous thromboembolic disease in association with different combined oral contraceptives. Br J Clin Pharmacol 2000; 49: 580-90.
13. Seaman HE, de Vries CS, Farmer RDT. The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyloestradiol (Dianette): a nested cohort analysis & case-control study using the GPRD. Hum Reprod 2003; 18: 522-526.
14. Vasilakis-Scaramozza C, Jick H. Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet 2001; 358: 1427-1429.
15. Van Staa T, Abenheim L. The quality of information on a UK database of primary care records: a study of hospitalizations due to hypoglycaemia and other conditions. Pharmacoepidemiol Drug Safe 1994; 3: 15-21.
16. Hollowell J. The General Practice Research Database: quality of morbidity data. Popul Trends 1997; 36-40.
17. Walley T, Mantgani A. The UK General Practice Research Database. Lancet 1997; 350: 1097-1099.
18. Lawrenson R, Todd JC, Leydon GM, Williams TJ, Farmer RD. Validation of the diagnosis of venous thromboembolism in general practice database studies. Br J Clin Pharmacol 2000; 49: 591-596.
19. British National Formulary. London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2003.
20. Roche Products Limited, UK. Summary of Product Characteristics. Roaccutane. http://www.rocheuk.com /ProductDB/Documents/rx/spc/Roaccutane_SPC.pdf. 1-1-2002.
21. Wycowski DK, Pitts M, Beitz J. An analysis of reports of depression and suicide in patients treated with isotretinoin. J Am Acad Dermatol 2001; 45: 515-519.
22. Jick SS, Kremers HM, Vasilakis-Scaramozza C. Isotretinoin use and risk of depression, psychotic symptoms, suicide, and attempted suicide. Arch Dermatol 2000; 136: 1231-1236.